Journal of Clinical Oncology
Articles in this Issue
Protein-bound paclitaxel/carboplatin compared to solvent-based paclitaxel/carboplatin in treatment of advanced stage of cervical cancer.
e17529 Background: In Uzbekistan, women with cervical cancer are often diagnosed in advanced stages of the disease. Cervical cancer is the leading cause o...
Effect of temozolomide on dendritic cell vaccine for glioblastoma.
e14638 Background: Glioblastoma is an aggressive, malignant intracranial tumor with an average survival of 14.6 months. The standard therapeutic approach...
Trends of colorectal cancer-related mortality among patients with comorbid type 2 diabetes in the United States, 1999–2020.
e15681 Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality in the United States. Type 2 diabetes (T2D), a prevalent comorbi...
Neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy—Clinical trial in progress.
TPS2099 Background: Gliomas are the most common primary central nervous system (CNS) malignancy in adults, accounting for 26.3% of all brain tumors. Care...
ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study.
4508 Background: Treatment options are limited for ccRCC after disease progression on immune checkpoint inhibitors (ICIs) and vascular endothelial growth...
Evolutionary divergence of the HLA-B genotype as a predictor of immune checkpoint inhibitor (ICI) therapy efficacy in hepatobiliary cancers.
4107 Background: The role of human leukocyte antigen class I (HLA-I) molecules in shaping the immune response to immune checkpoint inhibitors (ICIs) has b...
Toll-like receptor 7 (TLR7) agonists and OX40 agonists injection combined with SBRT in advanced tumor patients.
e14645 Background: Currently, the mainstream approach for in situ vaccines involves radiotherapy or intratumoral injection of immunologic adjuvants. Hypof...
Risk factors for cancer and screening tests in the population of the Pantanal, a rural region of Brazil: An update from the cohort study.
e13826 Background: Cancer remains a major public health challenge in Brazil, where disparities in access to prevention and screening persist despite natio...
A pilot study of Janus kinase 1 (JAK1) inhibitor itacitinib for treatment-refractory sarcomas: Leiomyosarcoma cohort.
11546 Background: Sarcomas are a heterogenous group of mesenchymal tumors. Although variable, many sarcoma subtypes have a high proportion of infiltrating...
Differential cardiotoxicity of acalabrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: A retrospective cohort study from 2000-2025 using TriNetX database.
e19022 Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia that originates by dysfunctional development of the lymphocytes. Acalabru...
Clinical study on splenic radiation dose constraints.
e16138 Background: Lymphocytes, known for their high sensitivity to radiation, are vital for the body's anti-tumor mechanisms. Radiation-induced lymphopen...
Accelerating answers: Impact of a quality improvement initiative for lung cancer pathology practices at the VA.
e23228 Background: Advances in lung cancer biology have enabled targeted therapies for patients with driver mutations. Pathology lab processes are critica...
Granisetron transdermal delivery system for nausea and vomiting prophylaxis in HER2-positive metastatic breast cancer patients receiving pyrotinib and capecitabine: A single-arm phase II study.
12069 Background: The efficacy of granisetron transdermal delivery system (GTDS) in managing nausea and vomiting caused by intravenous chemotherapy is wel...
Phase II trial of zanzalintinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).
TPS4216 Background: Despite the evolving novel treatment options, the prognosis for advanced hepatocellular carcinoma (HCC) remains poor, with a 4-year su...
Relationship between immune-mediated adverse events and clinical outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors (ICI): A single institution experience.
e21531 Background: ICI targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) revolutionized the treatm...
Real-world induction targeted therapy (TT) with immune checkpoint inhibitor (ICI) therapy switch in <i>BRAF</i> -mutant metastatic melanoma.
e21525 Background: Induction BRAF/MEK inhibitor (TT) with a planned switch to doublet ICI has been evaluated in 2 clinical trials of patients (pts) with m...
Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).
7527 Background: Etentamig (etenta) is a differentiated BCMA x CD3 bispecific T-cell engager composed of high avidity bivalent BCMA-binding domains, low-a...
Patient-reported pain and emergency department utilization in patients with newly diagnosed ovarian cancer: A retrospective cohort study.
11110 Background: Pain is one of the most common reasons for emergency department (ED) visits among patients with cancer. While patient-reported pain is i...
INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).
2007 Background: Recent cell therapy and CAR-T initiatives for GBM have shown initial responses but durability has been disappointing. We developed a nove...
Clinical and molecular features of concomitant EGFR and SMARCA4 mutations in an East Asian cohort.
e20645 Background: SMARCA4 is a subunit of the SWI/SNF complex and is frequently mutated in non-small cell lung cancer (NSCLC). Recent studies have identi...
Machine learning model to forecast patient availability for oncology clinical trials.
1566 Background: Automating eligibility criteria assessment for oncology clinical trials is an emerging application of machine learning (ML). However, mac...
The implications of using truncated Medicare definitions of avoidable hospital visits.
11087 Background: As part of the Outpatient Quality Reporting program, Medicare reports on potentially avoidable, acute hospital visits after chemotherapy...
Updated results of HLX22 plus trastuzumab and XELOX for first-line treatment of human epidermal growth factor receptor 2 (HER2)–positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC).
e16021 Background: HER2-positive (HER2+) G/GEJC accounts for 12–23% of G/GEJC cases. Survival outcomes with combined treatment of trastuzumab and chemothe...
Evaluation of a plasma cell-free DNA methylation-based multi-cancer detection test.
10550 Background: Blood-based multi-cancer detection (MCD) tests hold promise for early cancer detection. MCD tests should demonstrate high specificity, c...
Co-mutations in non small cell lung cancer: Real-world data and clinical insights from a tertiary care centre in western India.
e20689 Background: The management of non-small cell lung cancer (NSCLC) has advanced with molecular profiling and targeted therapies. However, complex cas...